Inventiva Strengthens Its Board Of Directors With The Appointment Of Five New Independent Directors
Daix (France) March 20, 2017 – Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, has today following the board meeting of February 14th, 2017 confirming the resolutions adopted during the ordinary and extraordinary general meetings held on September 30th, 2016, strengthened its Board of Directors with the appointment of five new independent directors.
These five new independent directors will serve alongside Frédéric Cren (Chairman of the Board and Chief Executive Officer), Pierre Broqua (Chief Operating Officer and Chief Scientific Officer) and Jean-Louis Junien (Senior Science Advisor and Director appointed in May 2016). The Board of Directors now has eight members, five of whom are independent. “On behalf of Inventiva’s entire team, I would like to express our delight that these five prominent industry figures, with their diverse range of international backgrounds, are joining our Board of Directors as independent directors. Their top-level experience in the biotechnology sector will help us to accelerate our development as we start to move forward as a listed company.” said Frédéric Cren, Chairman and Chief Executive Officer and co-founder of Inventiva.
Inventiva is a biopharmaceutical company specialised in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.
IVA337, its lead product, is an anti-fibrotic treatment with a strong action mechanism permitting the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing in parallel, a second clinical product, IVA336, which is a clinical program for the treatment of three different forms of mucopolysaccharidosis (MPS I or Hurler-Sheie syndrome, MPS II or Hunter syndrome and MPS VI also known as Maroteaux-Lamy syndrome), as well as a preclinical stage oncology portfolio.
Inventiva benefits from two partnerships with world-leading research entities such as the Institut Curie. Two strategic partnerships have also been developed with AbbVie and Boehringer Ingelheim, making Inventiva eligible for preclinical, clinical, regulatory and commercial milestone payments, in addition to royalties on the products resulting from these partnerships.
Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.
These five new independent directors will serve alongside Frédéric Cren (Chairman of the Board and Chief Executive Officer), Pierre Broqua (Chief Operating Officer and Chief Scientific Officer) and Jean-Louis Junien (Senior Science Advisor and Director appointed in May 2016). The Board of Directors now has eight members, five of whom are independent. “On behalf of Inventiva’s entire team, I would like to express our delight that these five prominent industry figures, with their diverse range of international backgrounds, are joining our Board of Directors as independent directors. Their top-level experience in the biotechnology sector will help us to accelerate our development as we start to move forward as a listed company.” said Frédéric Cren, Chairman and Chief Executive Officer and co-founder of Inventiva.
Inventiva is a biopharmaceutical company specialised in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.
IVA337, its lead product, is an anti-fibrotic treatment with a strong action mechanism permitting the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing in parallel, a second clinical product, IVA336, which is a clinical program for the treatment of three different forms of mucopolysaccharidosis (MPS I or Hurler-Sheie syndrome, MPS II or Hunter syndrome and MPS VI also known as Maroteaux-Lamy syndrome), as well as a preclinical stage oncology portfolio.
Inventiva benefits from two partnerships with world-leading research entities such as the Institut Curie. Two strategic partnerships have also been developed with AbbVie and Boehringer Ingelheim, making Inventiva eligible for preclinical, clinical, regulatory and commercial milestone payments, in addition to royalties on the products resulting from these partnerships.
Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.